Terms: = Prostate cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2 AND Treatment
3 results:
1. Post-transcriptional modification of m
Li Y; Zhu S; Chen Y; Ma Q; Kan D; Yu W; Zhang B; Chen X; Wei W; Shao Y; Wang K; Zhang M; Deng S; Niu Y; Shang Z
Cell Death Dis; 2023 Apr; 14(4):289. PubMed ID: 37095108
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2018 Nov; 129(2):370-376. PubMed ID: 30190166
[TBL] [Abstract] [Full Text] [Related]
3. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract] [Full Text] [Related]
